Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study
Table 1
Demographic, clinical, and work characteristics of study participants.
Bromhexine treatment group
Control group
Overall
n
25
25
50
1.00
Age (years)
41.7 ± 6.9
39.5 ± 8.2
40.6 ± 7.6
0.43
Sex, n (% of males)
11 (44%)
10 (40%)
0.78
BMI
25.1 ± 3.9
23.9 ± 4.1
24.6 ± 4.0
0.76
Work within the “red zone,” n (%)
14 (56%)
11 (44%)
25 (50%)
0.41
Comorbidity, n
2
1
3
0.82
ACEi2 inhibitors/ARA treatment, n
1
1
2
1.00
Additional pharmacological drugs, n
Vitamin D/C
1
4
5
0.16
Negative serologic test for anti-SARS-CoV-2 IgM and IgG at baseline
100%
100%
100%
1.00
Time spent in the “red zone,” mean SD; median [IQR] (hours)
64.1 ± 69.5; 40 [2; 144]
66.6 ± 78.2; 20 [3; 160]
66.1 ± 72.6; 30.0 [2; 144]
0.97
Time spent in the hospital (hours)
145.1 ± 44.5
143.2 ± 40.6
144.2 ± 42.2
0.66
Participants who worked in intensive care units, n
6
6
12
1.00
Participants who worked in repurposed infectious wards or COVID-19 admission departments, n
12
14
28
0.58
Participants who worked in invasive cardiology/electrophysiology departments, n
6
4
10
0.49
n, number of participants; BMI, body mass index; ACEi2, angiotensin 2 converting enzyme inhibitors; ARA, angiotensin receptor antagonists; SD, standard deviation; IQR, interquartile range; PCR, polymerase chain reaction.
